The 10 references in paper L. Ivanova A., A. Pakhomova N., Yu. Gavrilova M., A. Klimova S., O. Rostovtseva N., Л. Иванова А., А. Пахомова Н., Ю. Гаврилова М., А. Климова С., О. Ростовцева Н. (2015) “СПОРАДИЧЕСКИЙ МЕДУЛЛЯРНЫЙ РАК ЩИТОВИДНОЙ ЖЕЛЕЗЫ. КЛИНИЧЕСКИЙ СЛУЧАЙ // SPORADIC MEDULLARY THYROID CANCER. СASE REPORT” / spz:neicon:ogsh:y:2014:i:3:p:51-56

1
Газизова Д. О., Бельцевич Д. Г. Современный взгляд на проблему диагностики и лечения медуллярного рака щитовидной железы. Эндокринная хирургия 2013;3:4–21.
(check this in PDF content)
2
Абдулхабирова Ф. М., Бельцевич Д. Г., Ванушко В. Э. и др. Диагностика и лечение медуллярного рака щитовидной железы (Проект национальных клинических рекомендаций). Эндокринная хирургия 2012;1:5–17.
(check this in PDF content)
3
Lam E. T., Ringel M. D., Kloos R. T. Anti-tumor activity of Sorafenib in patients with metastatic medullary thyroid carcinoma. Proceedings of the American Association for Cancer Research 2009. Abstract 4513.
(check this in PDF content)
4
Papewalis C., Wuttke M., Seissler J. et al. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer. Clin Cancer Res 2008;14(13):4298–305.
(check this in PDF content)
5
Robinson B. G., Paz-Ares L., Krebs A. et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95(6): 2664–71.
(check this in PDF content)
6
Salgia R., Sherman S., Hong D. S. et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol 2008;26: Abstract 3522.
(check this in PDF content)
7
Wells S. A. Jr, Gosnell J. E., Gagel R. F. et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. ASCO Annual Meeting Proceedings Part I 2007;25:6016.
(check this in PDF content)
8
Wells S. A. Jr, Robinson B. G., Gagel R. F. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double_blind phase III trial. J Clin Oncol 2012;30(2):134–41.
(check this in PDF content)
9
Wells S., Gosnell J., Gagel R. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medul - lary thyroid cancer. J Clin Oncol 2010;28(5): 767–72. doi: 10.1200 / JCO. 2009.23.6604.
(check this in PDF content)
10
Xu L., Wang W. B., Zhao Y. P. et al. Medullary thyroid carcinoma with nodular goiter carries an excellent prognosis. J Surg Oncol 2012;106(2): 169–73.
(check this in PDF content)